Rovere R K
Klin Onkol. 2014;27(3):219-20.
To evaluate the role of bevacizumab and irinotecan as secondline treatment of glioblastoma in patients with progression after radiotherapy and temozolomide.
A retrospective analysis of 16 subjects was performed with overall survival and toxicity evaluation as the primary endpoint.
The analysis revealed serious toxicity of this highly expensive regimen without proving an improvement in overall survival of patients in comparison to a control group.
Unless there are robust data from phase III clinical trials, including quality of life assessments or evaluation of predictive bio-markers to guide therapy, bevacizumab and irinotecan regimen should be spared for cautiously selected patients, especially in countries with limited budget for oncological treatment.
评估贝伐单抗和伊立替康作为胶质母细胞瘤患者放疗和替莫唑胺治疗后进展的二线治疗的作用。
对16名受试者进行回顾性分析，以总生存期和毒性评估作为主要终点。
分析显示，与对照组相比，这种昂贵的治疗方案具有严重毒性，且未证明患者总生存期有所改善。
除非有来自III期临床试验的有力数据，包括生活质量评估或预测性生物标志物评估以指导治疗，否则贝伐单抗和伊立替康治疗方案应仅用于谨慎选择的患者，尤其是在肿瘤治疗预算有限的国家。
